Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Olanzapine/Zyprexa Clear all
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

NCT00034580
View directory record Official record
Conditions
Bipolar Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
21
States / cities
Berkley, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

NCT04524403
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorlilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 11, 2026, 5:59 AM EDT
Recruiting Phase 3 Interventional

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

NCT06482554
View directory record Official record
Conditions
Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions
Lumateperone 42 mg, Risperidone 2 mg
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

NCT02097823
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
Olanzapine, Aprepitant
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

SB-773812 Administered In Adults With Schizophrenia

NCT00259870
View directory record Official record
Conditions
Schizophrenia
Interventions
SB-773812, Olanzapine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

NCT00402324
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
olanzapine, placebo, divalproex
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

NCT02708394
View directory record Official record
Conditions
Adverse Effect of Other Antipsychotics and Neuroleptics, Insulin Resistance
Interventions
olanzapine, placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

NCT00094549
View directory record Official record
Conditions
Bipolar Disorder
Interventions
olanzapine, divalproex sodium, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
31
States / cities
Scottsdale, Arizona • Beverly Hills, California • Costa Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 11, 2026, 5:59 AM EDT
Withdrawn Not applicable Interventional

Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine

NCT00934908
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Green Tea, Placebo
Dietary Supplement · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED

NCT02643355
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Olanzapine, Clonidine
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

CAFE Comparison of Atypicals in First Episode of Psychosis

NCT00034892
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
Interventions
Olanzapine, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
24
States / cities
Stanford, California • Miami, Florida • Atlanta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 11, 2026, 5:59 AM EDT
Not listed Phase 4 Interventional

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

NCT03857581
View directory record Official record
Conditions
Psychosis, Substance Use Disorders
Interventions
Clozapine, Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Evans, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

Olanzapine in the Treatment of Anorexia Nervosa

NCT00592930
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
olanzapine, placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 23 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

NCT00351936
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 11, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

NCT06995508
View directory record Official record
Conditions
Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown Primary
Interventions
Best Practice, Olanzapine, Questionnaire Administration
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

NCT00183625
View directory record Official record
Conditions
Schizophrenia
Interventions
Individual Placement and Support (Supported Employment), Social Skills Training, Olanzapine, Risperidone
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

NCT00223418
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 52 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 11, 2026, 5:59 AM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 11, 2026, 5:59 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

NCT00211562
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Omega 3, Vitamin E+C
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

NCT03118986
View directory record Official record
Conditions
Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
Interventions
Olanzapine, Placebo Oral Tablet
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
30 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
San Francisco, California • Kansas City, Missouri • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

NCT00806234
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 19 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Janssen - Glucose Regulation/Risp/Olanz

NCT00205738
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Risperidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 11, 2026, 5:59 AM EDT